Prostaglandin E2, cyclic adenosine monophosphate and morphine analgesia

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Prostaglandin E2 (PGE2) is involved in central nervous system signaling.
• Cyclic adenosine monophosphate (cAMP) is a key second messenger in neuronal pathways.
• The interaction between PGE2, morphine, and cAMP in the brain is not fully understood.

Purpose of the Study:

• To investigate the distribution of intravenous PGE2 in the brain.
• To examine the effect of PGE2 on cAMP levels in specific brain regions.
• To determine the influence of acute morphine administration and morphine tolerance on PGE2-induced cAMP elevation.
• To assess the relationship between morphine-induced cAMP changes, naloxone antagonism, and analgesia.

Main Methods:

• Intravenous administration of prostaglandin E2 (PGE2) to mice.
• Measurement of PGE2 distribution in brain tissue.
• Assay of cyclic adenosine monophosphate (cAMP) levels in the midhindbrain and corpus striatum.
• Administration of acute morphine and induction of morphine tolerance.
• Administration of the narcotic antagonist naloxone.

Main Results:

• Intravenous PGE2 readily distributed into the mouse brain.
• PGE2 administration significantly elevated cAMP levels in the midhindbrain and corpus striatum.
• Neither acute morphine nor morphine tolerance altered the PGE2-induced elevation of cAMP.
• Morphine administration alone elevated cAMP levels, but only at supra-analgesic doses.
• Naloxone blocked morphine-induced cAMP elevations.

Conclusions:

• PGE2 effectively reaches the brain and modulates cAMP levels independently of acute morphine or morphine tolerance.
• Morphine-induced cAMP elevation is dose-dependent and sensitive to naloxone antagonism.
• Morphine analgesia does not correlate with either the elevation of cAMP levels or the antagonism of PGE2-induced cAMP increases.